SMYD2 and leukemia: When SMYD2 is downregulated, leukemia cells transition to a quiescent state after anti-leukemia chemotherapy treatment, resulting in increased resistance to anticancer drugs, which is thought to be due to increased SET7/9 expression in response to decreasing SMYD2 levels.